ANI Pharmaceuticals (ANIP) News Today $54.16 +0.81 (+1.52%) (As of 02:08 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Wellington Management Group LLP lowered its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 78.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,411 shares of theDecember 21 at 3:40 AM | marketbeat.comState Street Corp Acquires 58,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)State Street Corp raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 9.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 703,843 shares of the specialty pharmaceutical companDecember 21 at 3:24 AM | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Sells 7,500 SharesDecember 19, 2024 | insidertrades.comStephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.December 18, 2024 | marketbeat.comBarclays PLC Purchases 135,003 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Barclays PLC grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1,681.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,033 shares of the specialty pharmaceutical company's stockDecember 18, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 21.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 33,951 shares of the specialtDecember 16, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 12.8% in NovemberANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, a decrease of 12.8% from the November 15th total of 2,110,000 shares. Based on an average daily volume of 292,900 shares, the days-to-cover ratio is currently 6.3 days.December 15, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $60,000.00 in StockDecember 13, 2024 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) Raised to Strong-Buy at Leerink PartnrsDecember 13, 2024 | americanbankingnews.comLeerink Partnrs Upgrades ANI Pharmaceuticals (NASDAQ:ANIP) to "Strong-Buy"Leerink Partnrs raised shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday.December 12, 2024 | marketbeat.comLeerink Partners Initiates Coverage of ANI Pharmaceuticals (ANIP) with Outperform RecommendationDecember 12, 2024 | msn.comANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Leerink PartnersLeerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday. They set an "outperform" rating and a $80.00 price objective on the stock.December 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 8,869 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Charles Schwab Investment Management Inc. lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oDecember 8, 2024 | marketbeat.comHotchkis & Wiley Capital Management LLC Purchases New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Hotchkis & Wiley Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 52,080 shares of the specialtyDecember 7, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from BrokeragesANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on thDecember 2, 2024 | marketbeat.comMartingale Asset Management L P Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Martingale Asset Management L P grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 65.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,740 shares of the specialty pharmDecember 1, 2024 | marketbeat.comBank of Montreal Can Makes New $13.04 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Bank of Montreal Can purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 221,896 shares of the specialty pharmaceutical company's stock, valuDecember 1, 2024 | marketbeat.comIntech Investment Management LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intech Investment Management LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 12,593 shares of the specialty pharmaceutical company's stock, valued at aNovember 30, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 2.9% - Here's What HappenedANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 2.9% - Should You Sell?November 29, 2024 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells 33,481 Shares of StockNovember 28, 2024 | insidertrades.comRubric Capital Management LP Lowers Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Rubric Capital Management LP decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 90.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,671 shares of the specialty pharmaceNovember 27, 2024 | marketbeat.comANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comEagle Asset Management Inc. Purchases New Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Eagle Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 35,630 shares of the specialty pharmaceutiNovember 26, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Pacer Advisors Inc.Pacer Advisors Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23,259.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 568,343 shares of the specialty pharmacNovember 23, 2024 | marketbeat.comThompson Siegel & Walmsley LLC Has $13.73 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 230,159 shares of theNovember 21, 2024 | marketbeat.comANI Pharmaceuticals Advances Amidst Regulatory and Market ChallengesNovember 21, 2024 | markets.businessinsider.comGlobal Alpha Capital Management Ltd. Has $32.01 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 536,450 shares of the specialty pharmaceutical company's stock after acquiringNovember 20, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Growth in Short InterestANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,160,000 shares, an increase of 5.4% from the October 15th total of 2,050,000 shares. Based on an average daily volume of 310,500 shares, the days-to-cover ratio is presently 7.0 days.November 17, 2024 | marketbeat.comMizuho Markets Americas LLC Buys Shares of 195,613 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Mizuho Markets Americas LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 195,613 shares of the specialty pharmaceutical company's stock, vNovember 16, 2024 | marketbeat.comLisanti Capital Growth LLC Has $890,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Lisanti Capital Growth LLC lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 70.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 14,920 shares of the specialty pharmaceutical company's stock after selling 36,November 12, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comANI Pharmaceuticals: Buy Rating Backed by Consistent Revenue Growth, Strategic Acquisitions, and Strong Market PositionNovember 11, 2024 | markets.businessinsider.comTruist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)November 11, 2024 | markets.businessinsider.comANI Pharmaceuticals (NASDAQ:ANIP) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday.November 11, 2024 | marketbeat.comSummit Global Investments Raises Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Summit Global Investments lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 154.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,704 shares of the specialty pharmaceutical company's sNovember 9, 2024 | marketbeat.comANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up - Here's WhyANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Up - Here's What HappenedNovember 8, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings GuidanceANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance. The company provided EPS guidance of $4.90-5.05 for the period, compared to the consensus estimate of $4.72. The company also issued revenue guidance of $594-602 millionillion, compared to the consensus estimate of $590.33 millionillion.November 8, 2024 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Updates FY 2024 Earnings GuidanceANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2024 earnings guidance. The company provided EPS guidance of 4.900-5.050 for the period, compared to the consensus estimate of 4.720. The company also issued revenue guidance of $594.0 millionillion-$602.0 millionillion, compared to the consensus estimate of $590.3 millionillion.November 8, 2024 | marketbeat.comANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 GuidanceNovember 8, 2024 | globenewswire.comANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Report Preview: What To ExpectNovember 8, 2024 | finance.yahoo.comA Peek at ANI Pharmaceuticals's Future EarningsNovember 7, 2024 | benzinga.comANI Pharmaceuticals Q3 2024 Earnings PreviewNovember 7, 2024 | msn.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of "Moderate Buy" from BrokeragesANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assNovember 7, 2024 | marketbeat.comANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in NovemberNovember 4, 2024 | globenewswire.comF M Investments LLC Purchases Shares of 61,782 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)F M Investments LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 61,782 shares of the specialty pharmaceutical company's stock, valued at approxiNovember 3, 2024 | marketbeat.comANI Pharmaceuticals Is Acting Like It Is Being AcquiredNovember 2, 2024 | seekingalpha.comANI Pharmaceuticals (ANIP) Set to Announce Earnings on FridayANI Pharmaceuticals (NASDAQ:ANIP) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.November 1, 2024 | marketbeat.comANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ETOctober 30, 2024 | globenewswire.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 9.7% in OctoberANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,050,000 shares, a drop of 9.7% from the September 30th total of 2,270,000 shares. Based on an average daily volume of 352,600 shares, the days-to-cover ratio is currently 5.8 days.October 30, 2024 | marketbeat.com Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Coin for November 2024 (Ad)Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… ANIP Media Mentions By Week ANIP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIP News Sentiment▼1.160.60▲Average Medical News Sentiment ANIP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIP Articles This Week▼65▲ANIP Articles Average Week Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcellx News ADMA Biologics News Ultragenyx Pharmaceutical News Apellis Pharmaceuticals News Biohaven News Scholar Rock News Immunovant News Avidity Biosciences News Organon & Co. News PTC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIP) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
